The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin
- 11 November 2006
- journal article
- research article
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 374 (3) , 195-206
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertensionAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2006
- Early Effects on Endothelial Function of Atorvastatin 40 mg Twice Daily and Its WithdrawalThe American Journal of Cardiology, 2006
- A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertensionAmerican Heart Journal, 2006
- Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease preventionAmerican Heart Journal, 2006
- Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic MechanismsNature Reviews Drug Discovery, 2005
- Intermolecular Differences of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Contribute to Distinct Pharmacologic and Pleiotropic ActionsThe American Journal of Cardiology, 2005
- Statins as antioxidant therapy for preventing cardiac myocyte hypertrophyJournal of Clinical Investigation, 2001
- Clinical Pharmacokinetics of PravastatinClinical Pharmacokinetics, 2000
- Rac1 Disrupts p67phox/p40phox Binding: A Novel Role for Rac in NADPH Oxidase ActivationBiochemical and Biophysical Research Communications, 1999
- A factor preventing the major head protein of bacteriophage T4 from random aggregationJournal of Molecular Biology, 1970